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fect on HRQOL for patients at high-risk for drug-related
problems.
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OBJECTIVES: To gain an understanding of quality mea-
surement as it relates to effectiveness for the delivery of
health services across ambulatory and inpatient sites of
care. The goal is to measure quality through process con-
trol where quality reduction is signaled by departures
from the intended course of treatment. METHODS:
Eighteen months of encounter and claims data covering
over two million lives were assembled into episodes of
care (EOCs) that group together all of the services used
to treat a patient in a clinically homogeneous group de-
fined by intention to treat. EOCs were characterized by a
set of intensity measures (physician RVUs, resource utili-
zation, and costs) and encounter types (hospitalizations,
readmissions, ER visits, etc). Controlling for patient risk,
using multiple regression analysis of demographic and
clinical factors, the dimensions of the care process were
combined into a multivariate performance measure that
recognizes treatment hierarchies and the trade-offs be-
tween prevention and rework. Validation was by strati-
fied sample consistency tests. RESULTS: Treatment in-
tensity and duration measures for EOCs are highly
variable across patients within a given Common Treat-
ment Category, even after controlling for patient risk;
and they are not highly correlated with each other, indi-
cating substantial variation in practice patterns. Multi-
variate performance measures, based on trade-offs be-
tween prevention and rework, identified episode groupings
with statistically significant departures from norms. Vali-
dations showed robust clustering of practice patterns
around the incidence of rework. CONCLUSIONS: A
useful quality indicator can be tailored to the specific cir-
cumstances of care by grouping episodes of care by treat-
ment type and by accounting for the characteristics of the
patient. EOC grouping, when risk adjusted, can be used
to assess the effectiveness of health care by identifying
practices that deviate significantly from norms.
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The deleterious effects of non-compliance have been well
documented. OBJECTIVES: To determine compliance
and persistence with initial therapy at 6 and 12 month in-
tervals for twice daily and once daily (XR) medication
regimens using glipizide and venlafaxine. METHODS: A
retrospective database review identified newly treated Di-
abetes and Depression patients. Filled prescriptions served
as a proxy for compliance and persistency. Continuous
eligibility was required. Patients on greater than twice
daily regimen were excluded. Patients with a gap of 2.5X
days supply were deemed non-persistent implying a toler-
ance level of compliance down to 40%. A two-sample
student’s t-test was performed at the 6 and 12 month in-
terval to detect statistical significance. Evaluable patients
at 6 months for glipizide qd was 13,580 while 287 twice
daily glipizide patients were identified. Evaluable patients
for the venlafaxine comparison at 6 months was 2,412
for the once daily formulation and 616 for the twice daily
formulation. RESULTS: The glipizide once daily group
exhibited higher compliancy at the 6th (13% higher, P 
0.01) and 12th (20% higher, P  0.01) month interval
versus glipizide twice daily. The glipizide once daily
group had a 37% higher (P  0.01) persistency rate at 12
months vs the twice daily group. Venlafaxine once daily
improved compliance by 14% at 6 months, and 11% at
12 months while persistency was 6% higher at 12
months for the once daily group. CONCLUSIONS: Sim-
plifying regimen complexity from twice a day to once a
day yields substantial benefits for compliance, persis-
tency, and ultimately, should positively impact efficacy
rates.
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